Cancer therapy

Abstract

The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.

1 .- 89 . (canceled) 
     
     
         90 . A pharmaceutical composition comprising genistein, alpha lipoic acid, metformin, and cyclophosphamide. 
     
     
         91 . The pharmaceutical composition of  claim 90 , wherein the cyclophosphamide is present in an amount of 25 mg. 
     
     
         92 . The pharmaceutical composition of  claim 90 , wherein the cyclophosphamide is present in an amount of 50 mg. 
     
     
         93 . The pharmaceutical composition of  claim 90 , wherein the metformin is present in an amount of 50-2000 mg. 
     
     
         94 . The pharmaceutical composition of  claim 90 , wherein the metformin is present in an amount of 500-1000 mg. 
     
     
         95 . The pharmaceutical composition of  claim 90 , wherein the metformin is present in an amount of 500 mg. 
     
     
         96 . The pharmaceutical composition of  claim 90 , wherein the alpha-lipoic acid is present in an amount of 300-1200 mg. 
     
     
         97 . The pharmaceutical composition of  claim 90 , wherein the pharmaceutical composition is in solid form. 
     
     
         98 . The pharmaceutical composition of  claim 90 , wherein the pharmaceutical composition has been formulated for oral administration. 
     
     
         99 . The pharmaceutical composition of  claim 90 , wherein the pharmaceutical composition is a bolus that has been formulated for application to the tongue. 
     
     
         100 . The pharmaceutical composition of  claim 90 , wherein the pharmaceutical composition is a powder that has been formulated for application to the tongue. 
     
     
         101 . The pharmaceutical composition of  claim 90 , wherein the pharmaceutical composition has been formulated as a unit dose. 
     
     
         102 . The pharmaceutical composition of  claim 90 , wherein the alpha-lipoic acid is R-alpha-lipoic acid. 
     
     
         103 . The pharmaceutical composition of  claim 90 , further comprising curcumin. 
     
     
         104 . A combination therapy comprising:
 (i) the pharmaceutical composition of  claim 90 ,   (ii) curcumin,   (iii) genistein,   (iv) melatonin, and   (v) naltrexone.   
     
     
         105 . A method comprising administering the pharmaceutical composition of  claim 90  to a subject having cancer. 
     
     
         106 . A method comprising administering the combination therapy of  claim 104  to a subject having cancer.